FDA 483 OBSERVATION · #465 OF 1,932 MOST-CITED

Accurate, indelible, legible

FDA cited this observation 54 times across 49 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation54
BY FISCAL YEAR
FY20262
FY20259
FY20247
FY202310
FY20222
FY20211
FY20204
FY20195
FY20188
FY20171
FY20165

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.8× the rate of the average FDA-cited firm (6.1% vs 7.8%), across 49 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Donor eligibility records are not accurate.

Southwest Fertility Center · Phoenix, Arizona · Human Tissue for Transplantation · 2026-04-14

Donor eligibility records are not accurate.

Aligneage Fertility Laboratory, LLC · New York, New York · Human Tissue for Transplantation · 2025-10-21

Records were not accurate.

Hans Biomed Corporation · Yuseong District · Human Tissue for Transplantation · 2025-09-12

Records were not accurate.

Eurofins Donor & Product Testing, LLC, San Ramon · San Ramon, California · Human Tissue for Transplantation · 2025-07-18

Donor eligibility records are not accurate, indelible and legible.

Fort Worth Fertility P.A. · Fort Worth, Texas · Human Tissue for Transplantation · 2025-04-24

Donor eligibility records are not accurate, indelible and legible.

Kofinas Fertility Group · New York, New York · Human Tissue for Transplantation · 2025-04-09

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →